163 related articles for article (PubMed ID: 1900516)
1. High resolution analysis of functional determinants on human tissue-type plasminogen activator.
Bennett WF; Paoni NF; Keyt BA; Botstein D; Jones AJ; Presta L; Wurm FM; Zoller MJ
J Biol Chem; 1991 Mar; 266(8):5191-201. PubMed ID: 1900516
[TBL] [Abstract][Full Text] [Related]
2. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
3. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties.
Berg DT; Burck PJ; Berg DH; Grinnell BW
Blood; 1993 Mar; 81(5):1312-22. PubMed ID: 8382971
[TBL] [Abstract][Full Text] [Related]
4. Tissue-type plasminogen activator mutants imitating urokinase in the peptide link between kringle and protease domains and at selected sites within the protease domain.
Hinzmann B; Wernicke D; Pfeifer M; Zacharias U; Fischer B; Eisenmenger F; Will H
Eur J Biochem; 1993 Apr; 213(1):437-43. PubMed ID: 8386628
[TBL] [Abstract][Full Text] [Related]
5. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
Rydzewski A; Castellino FJ
Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682
[TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.
Novokhatny V; Medved L; Lijnen HR; Ingham K
J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771
[TBL] [Abstract][Full Text] [Related]
7. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin.
Verheijen JH; Caspers MP; Chang GT; de Munk GA; Pouwels PH; Enger-Valk BE
EMBO J; 1986 Dec; 5(13):3525-30. PubMed ID: 3030730
[TBL] [Abstract][Full Text] [Related]
8. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
[TBL] [Abstract][Full Text] [Related]
9. Interactions between the finger and kringle-2 domains of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Kaneko M; Sakata Y; Matsuda M; Mimuro J
J Biochem; 1992 Feb; 111(2):244-8. PubMed ID: 1314812
[TBL] [Abstract][Full Text] [Related]
10. Tissue-type plasminogen activator variants with domain duplications and rearrangements.
Markland W; Pollock D; Livingston DJ
Protein Eng; 1989 Nov; 3(2):111-6. PubMed ID: 2556697
[TBL] [Abstract][Full Text] [Related]
11. Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.
Wilhelm OG; Jaskunas SR; Vlahos CJ; Bang NU
J Biol Chem; 1990 Aug; 265(24):14606-11. PubMed ID: 2117612
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L
J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.
de Serrano VS; Castellino FJ
J Biol Chem; 1990 Jun; 265(18):10473-8. PubMed ID: 2113057
[TBL] [Abstract][Full Text] [Related]
14. The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator.
Bakker AH; Rehberg EF; Marotti KR; Verheijen JH
Protein Eng; 1995 Mar; 8(3):293-300. PubMed ID: 7479691
[TBL] [Abstract][Full Text] [Related]
15. Making tissue-type plasminogen activator more fibrin specific.
Paoni NF; Chow AM; Peña LC; Keyt BA; Zoller MJ; Bennett WF
Protein Eng; 1993 Jul; 6(5):529-34. PubMed ID: 8415579
[TBL] [Abstract][Full Text] [Related]
16. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains.
Larsen GR; Henson K; Blue Y
J Biol Chem; 1988 Jan; 263(2):1023-9. PubMed ID: 3121618
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue-type plasminogen activator.
Wojta J; Beckmann R; Turcu L; Wagner OF; van Zonneveld AJ; Binder BR
J Biol Chem; 1989 May; 264(14):7957-61. PubMed ID: 2470738
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
[TBL] [Abstract][Full Text] [Related]
19. The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin.
Nesheim M; Fredenburgh JC; Larsen GR
J Biol Chem; 1990 Dec; 265(35):21541-8. PubMed ID: 2123871
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of the amidolytic activity of single chain tissue-type plasminogen activator by fibrinogen degradation products: possible fibrin binding sites on single chain tissue-type plasminogen activator molecule.
Urano T; Takada Y; Takada A
Biochim Biophys Acta; 1991 Apr; 1077(3):245-52. PubMed ID: 1903067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
